Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...

CRISPR-based Spotlight Therapeutics has shut down, former CEO Mary Haak-Frendscho, Ph.D., confirmed with Fierce Biotech. | ...

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated ...

Medics in the UK have become the first in the world to successfully administer a pioneering gene therapy that preserves sight in young children with an extremely rare genetic condition that usually ...

Amicus Therapeutics has two products in the market that generated more than $528 million in revenue last year.

According to Brown, the U.K.’s new Labor government has continued a pledge by the previous administration to invest £520 million in life sciences manufacturing. In addition, British gene and cell ...

The Philadelphia market has gained recognition not only for its cell and gene therapy sector but also its real estate scene and talent pool. Vittoria Biotherapeutics, Interius BioTherapeutics and ...

Story Feb. 13 - Encoded Therapeutics: The gene therapy biotech is laying off 29% of staffers as it focuses resources toward its Dravet syndrome program. Most of the affected roles will be in ...